(, , , )
302 , R657R666 (2011)
Common experiences include: Injection site reactions: Redness, minor swelling, tenderness (resolves within hours) Transient fatigue: Mild tiredness during first 1 to 2 weeks, especially with TB-500 Headaches: Occasional mild headaches, typically in early use Vivid dreams: Some users report more memorable or intense dreams Temporary water retention: Minor and resolves with continued use Serious adverse events with healing peptides remain rare in documented use
doi: 10.3389/fimmu.2025.1711756 Received 23 September 2025 Accepted 31 October 2025 Published 19 November 2025 Volume 16 - 2025 Edited by Jean-louis Mege, Aix-Marseille Universit, France Reviewed by Nadja Freund, Ruhr University Bochum, Germany Namrata Anand, University of Chicago Medical Center, United States Updates Copyright 2025 Su, Li, Yang, Yang, Wang, Ren, Bao, Lao and Luan